PCM
INMB icon

Prelude Capital Management’s INmune Bio INMB Stock Holding History

Prelude Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,406
Closed -$57.9K – 1357
2024
Q4 		$57.9K Buy
12,406
+1,679
+16% +$8.75K ﹤0.01% 1141
2024
Q3 		$57.8K Buy
+10,727
New +$76.3K ﹤0.01% 1203

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's INMB Position: Q1 2025 in Review

Prelude Capital Management sold out of INmune Bio (INMB) in Q1 2025, closing a stake of 12,406 shares — an estimated $57.9K sold.

Prelude Capital Management first reported a position in INMB in Q3 2024 and held it in 2 quarters. The position peaked at $57.9K in Q4 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2025.

  • Prelude Capital Management reported no remaining INmune Bio position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 12,406 INmune Bio shares in Q1 2025, an estimated $57.9K.
  • Prelude Capital Management first reported a position in INmune Bio in Q3 2024 and held it in 2 quarters.
  • Prelude Capital Management's INmune Bio position peaked at $57.9K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.